Newsletter May 15, 2020

Wuhan's Psychedelics
Cannabinoids Ongoing Research

It's time we get back to our roots: Nature’s plant-based medicines, Magic Mushrooms and their psychoactive ingredient – psilocybin.    


What are magic mushrooms and psilocybin

Psilocybin is a classic hallucinogenic compound produced by over 100 species of mushrooms. It has a strong effect on serotonin receptors in the brain, including some in the cerebral cortex and thalamus regions.

Psilocybin mushrooms also have some powerful therapeutic benefits. Researchers are diving into their potential to treat numerous disorders. Areas of interest include conditions like mood disorders, anxiety, OCD, and addiction. 


Currently, psilocybin-containing mushrooms are illegal in the United States and are listed as a Schedule 1 drug. Even mushroom spores, which don’t contain any psychoactive chemicals yet, are illegal in many states. A few cities – Denver, Oakland and Santa Cruz – have decriminalized mushrooms, meaning you won’t get arrested for possessing them but there are no legal avenues through which to purchase or sell them either. Oregon has plans to legalize mushrooms entirely, however, these plans have been put on the back-burner amid the current pandemic.


Potential Medical Benefits

Although there are many possible uses for psilocybin, at the moment, it’s most frequently used to treat conditions relating to mental health. Depression, PTSD and anxiety are among the most researched indications for psilocybin treatment. 

Another possible use for psychedelic mushrooms is in the cessation of smoking, alcoholism, and other addictions. 

It’s also being looked at as a possible treatment for certain types of cancers, heart disease, inflammation, and many other conditions. 

Understanding exactly how psilocybin works will help discover and develop the best treatments to help patients.


Psychedelic Research and Clinical trial?


Our collaborative work with scientists from the Pretoria University of South Africa gives a significant boost to research into the chemistry and pharmacology of psychedelics. 

Our ongoing magic mushroom psilocybin clinical trial:


‘’Isolation of psilocybin from genus of Psilocybe and Panaeolus mushroom extracts and investigating their micro-dosing effects and their underlying mechanisms towards depression and the cardiovascular risks in vivo on rats and in vitro on cell lines.’’ 




The study aims to investigate the effect of different drying methods on the extract composition and the differences in concentration levels of psilocybin in four magic mushroom species (Panaeolus cyanescens, Psilocybe natalensis, Psilocybe cubensis A+ strain and Psilocybe cubensis). The effect of micro-dosing psilocybin mushrooms on depression and the underlying effect of psilocybin on nerve conduction and cardiac excitability, and finally the micro-dosing effects of psilocybin towards depression and its cardiovascular effect in vivo on Wistar normotensive rats and in vitro on the 5-HT2B serotonin receptor cell line, a cardiac-myoblast cell line, animal and human endothelial cell line.


The in vitro and in vivo animal studies were successfully concluded, and results are being compiled and the findings to be published mid-year and expected to be presented at a conference for cardiology in September this year.


With our remarkable results, the protocol for phase I human trial is now being set and is scheduled to begin late 2020 or early 2021.


Our objective is to develop intellectual proprietary focused on psilocybin and psychedelic medical research for medical applications like drug and alcohol addiction, mental disorder, depression and commercialization of such IP. 


Some Next Steps?  

Wuhan is looking at how certain blends of cannabinoids, plant-based medicine, and mushrooms could effectively treat a variety of chronic and inflammatory medical conditions like colon cancer, IBS and cardiovascular disease. We plan to start clinical trials with cannabinoids in early 2021. 

The Wuhan Team wishes everybody all the very best in health and happiness.




 Dr. Anna Morera Leralta                                      

Twitter Twitter
LinkedIn LinkedIn
Facebook Facebook

                     Wuhan General Group, Inc.  |  6500 Transcanada Hwy 400   |  Quebec, Canada H9R0A5


Copyright © 2020 Wuhan General Group or its affiliates. All rights reserved. Medspresso, the logo, and all other related logos are trademarks of Wuhan General Group Inc or its affiliates.

You've received this email because  you opted in via our website or have shown an interest in the past. If you wish to change how you receive these emails?
You can update your preferences or unsubscribe from this list.


Email Marketing Powered by Mailchimp